Can adding radiation boost the power of immunotherapy in advanced cervical cancer?
NCT ID NCT06543576
First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time
Summary
This trial is investigating whether adding radiation therapy to a standard combination of chemotherapy and two targeted drugs can improve outcomes for people with stage IVB cervical cancer. The study combines external beam radiation and internal brachytherapy with cisplatin, paclitaxel, bevacizumab, and pembrolizumab. The goal is to see if this multi-pronged approach is safe and effective in controlling the disease and extending survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Combination of external beam radiation therapy, brachytherapy, cisplatin, paclitaxel, bevacizumab, and pembrolizumab
- What this could lead to
- If successful, this approach could offer a more effective treatment option for stage IVB cervical cancer, potentially extending life and delaying disease progression.
- What could go wrong
- This is an early-phase trial with a small number of participants, so results may not be conclusive. Combining multiple treatments may increase side effects, and the added benefit of radiation is not yet proven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UCLA / Jonsson Comprehensive Cancer Center
RECRUITINGLos Angeles, California, 90095, United States
-
University of California San Diego (UCSD)
NOT_YET_RECRUITINGSan Diego, California, 96960, United States
-
University of Oklahoma Health Sciences Center
NOT_YET_RECRUITINGOklahoma City, Oklahoma, 73104, United States
-
University of Virginia Cancer Center
NOT_YET_RECRUITINGCharlottesville, Virginia, 22908, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an immunotherapy-angiogenesis combo outshine standard chemo for advanced cervical cancer?
- Can a Two-Pronged attack shrink Hard-to-Treat cancers?
- Timing matters: early platelet booster may prevent dangerous drops in cervical cancer treatment
- Can we predict who will benefit from immunotherapy? new study aims to find out.
- New drug cocktail targets Hard-to-Treat cancers
- New smart chemo targets tumors, spares healthy tissue